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Abstract 
The evidence on the efficacy of nondihydropyridine calcium channel blockers (CCBs) 
compared to beta-blockers (BBs) for acute atrial fibrillation (AF) rate control in the 
emergency department setting was examined. Twelve studies were relevant and revealed that 
CCBs, specifically diltiazem, were superior to BBs because of their rapid onset of action and 
the lower number of doses they required to sustain ventricular rate control compared to BBs. 
However, given the small sample sizes in these studies and the limited number of 
randomized, double-blinded trials, more research is needed to increase the generalizability 
and to confirm the significance of these findings.   
 
INTRODUCTION 
Atrial fibrillation with a rapid ventricular response (AF with RVR) is one of the most 
commonly encountered dysrhythmias in the emergency department (ED) and is responsible for 
over 750,000 hospitalizations each year.1 Left uncontrolled, AF with RVR often results in 
complications such as hemodynamic instability, worsening or new onset cardiomyopathy and 
heart failure, stroke, and increased mortality rates and hospital costs. Therefore, properly 
recognizing and understanding how to treat AF with RVR is crucial to patient care and 
management.  AF is traditionally defined as an irregularly irregular rhythm with no discernible 
p-waves and a ventricular conduction rate greater than 120 bpm. The American Cardiology 
Association (ACA) released guidelines in 2014 with recommendations to treat AF with RVR 
with either nondihydropyridine calcium channel blockers (CCB) or beta-blockers (BB). Beta-
blockers are administered intravenously in the acute ED setting. The most commonly used 
agents are metoprolol, propranolol, and esmolol.  Beta-blockers work by blocking sympathetic 
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tone, thereby decreasing the ventricular rate.  Nondihydropyridine CCBs are also administered 
intravenously in acute settings. The most commonly used agents are diltiazem and verapamil.  
Nondihydropyridine CCBs have direct AV nodal effects, blocking L-type calcium channels, 
and are used to control the ventricular rate.2 While both BBs and CCBs are approved for clinical 
practice, considerable variation and minimal guidance are available for their use in the ED 
setting. Furthermore, variability in patients who present with AF with RVR, including their 
demographics and co-morbidities, may affect the effectiveness of CCBs or BBs. To date, a 
limited number of studies compare the effectiveness of CCBs versus BBs in the ED setting; 
even fewer examine how comorbidities affect the efficacy of CCBs or BBs. Whether CCBs are 
more effective than BBs for the acute management of A-fib with RVR in ED patients is 
examined for the purpose of determining not only which medications are more effective but 
also in which patients these drugs are more beneficial.   A better understanding of the efficacies 
overall and the benefits in specific populations can lead to improved mortality rates, reduced 
complications and decreased costs for both patients and hospitals.                     
DISCUSSION 
In order to ascertain which class of drugs is better, studies that addressed the efficacy 
of rate-control agents, specifically CCBs and BBs, for the acute management of AF with RVR 
were reviewed. Search engines included PubMed, ScienceDirect, and Google Scholar. 
Keywords used were “AF with RVR”, “rate-control”, “CCB”, and “BB”. Studies were included 
if the authors discussed the efficacy of acute rate control of AF with RVR using either CCBs 
or BBs. Studies were excluded if they were older than 2014, as the ACA guidelines for the 
treatment of AF with RVR were different prior to 2014. A total of 12 articles were found that 
met these criteria. High-quality studies, particularly meta-analyses and blinded randomized 
controlled trials when available, were preferred.   
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Current ACA guidelines recommend treatment for acute rate control of AF with RVR 
using a nondihydropyridine CCB or a BB. However, neither adequate guidance nor 
standardized practice recommendations are currently available for choosing a given drug in 
specific situations. The focus on patients in the ED setting was chosen for this inquiry because 
patients in AF with RVR tend to present to the ED initially for acute management and 
stabilization. A systematic review by Martindale et al included two randomized controlled trials 
(Demircan et al and Fromm et al), and compared the efficacy of IV diltiazem versus IV 
metoprolol for rate control in the ED setting. The evidence in both studies showed that IV 
diltiazem was superior for ventricular rate control in terms of onset of action, sustained rate 
control, and number of doses required. Diltiazem worked more rapidly with fewer doses for 
longer durations than metoprolol. In both studies, sustained rate control was defined as a 
ventricular rate less than 110 bpm persisting without the need for additional doses. Of note, no 
statistically significant differences in adverse reactions, defined as bradycardia or hypotension, 
were found between IV diltiazem and IV metoprolol.3,4,5  
While the Martindale et al’s study has high-quality evidence, some limitations need to 
be addressed. First and most noteworthy was the small sample size; only two studies were 
analyzed. Secondly, Martindale et al excluded patients with concomitant conditions such as 
heart failure, lung diseases, and diabetes mellitus. These encumbrances greatly decrease the 
power (internal validity) and generalizability (external validity) for effectively interpreting the 
results. Larger and more diverse populations examined in randomized, double-blinded studies 
are needed for more useful conclusions. Furthermore, these limitations are troublesome as 
many patients who present with AF with RVR often have long-standing comorbidities such as 
coronary artery disease, hypertension, hypothyroidism, diabetes, and obesity. Many of these 
conditions have relative contraindications to either CCBs, BBs, or both, which would bias the 
choice of drug used to treat the AF with RVR. In fact, evidence from a retrospective cohort 
   
4 
 
study by Hines et al. showed that most ED clinicians based their initial drug therapy for acute 
rate control of AF with RVR on patient’s home medications.6 For example, in this study, ED 
clinicians treated patients on home-therapy BB with IV metoprolol and likewise those on CCB 
at home with IV diltiazem. Therefore, it is important to consider how a patient’s home 
medications can influence the choice of whether a CCB or a BB is used in the acute setting.  
Two studies examined the effect of home medications on acute treatment of AF with 
RvR. The first was a single-center retrospective cohort study conducted by Kuang et al on the 
effectiveness of IV metoprolol for the treatment of AF with RVR in BB-naïve patients versus 
BB-chronic use patients. Beta-blocker naïve patients were defined as individuals who had not 
used any BB within the past 5 days. Beta-blocker chronic patients were defined as those who 
had used a BB within the past 5 days of admission. Compared to the BB chronic use patients, 
the BB naïve patients had a greater response to IV metoprolol in achieving control of the 
ventricular rate of AF with RVR in the ED setting.7 The second investigation was also a single-
center retrospective cohort study by Feeney et al that examined whether chronic BB users had 
better rate control with IV diltiazem versus IV metoprolol in the ED setting. The authors found 
that IV diltiazem had a faster onset of action but produced a higher rate of hypotension in 
chronic BB patients. Otherwise, there was no statistical difference between IV diltiazem versus 
IV metoprolol for rate control.8 From these two studies, it can be deduced that BB naïve patients 
responded better to IV metoprolol compared to IV diltiazem for acute management of AF with 
RVR in the ED setting. However, in chronic BB users, efficacy and adverse reactions were 
similar for IV diltiazem and IV metoprolol. Even though efficacies may differ, both drugs can 
be used safely with the exception of IV diltiazem in chronic BB patients.  
A second consideration is whether heart failure with reduced ejection fracture (HFrEF) 
can affect the efficacy or limit the safety of CCBs and BBs.  In HFrEF patients, CCBs are 
relatively contraindicated due to their negative inotropic effects. However, as noted previously, 
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IV diltiazem is the preferred and more commonly used agent for AF with RVR in the ED 
setting. Thus, with this comorbidity, it is necessary to determine whether CCBs, especially IV 
diltiazem, are equally effective and safe compared to BBs such as IV metoprolol. A single-
center retrospective cohort study in HFrEF patients by Hirschy et al addressed this issue and 
revealed that IV diltiazem achieved similar rate control with no increase in adverse events when 
compared to IV metoprolol for AF with RVR.9 Interestingly, ACA recommendations contrast 
with the Hirschey et al findings and suggest using BBs for HFrEF.  Thus, clinicians should 
proceed with caution when treating HFrEF patients presenting with AF with RVR.  
The other common presenting comorbidity found AF with RVR patients is obstructive 
lung disease (OLD), which includes asthma and emphysema or chronic obstructive pulmonary 
disease (COPD). In OLD, BBs are relatively contraindicated because they can induce or 
exacerbate bronchospasm. To date, studies on the treatment of AF with RVR in ED patients 
with OLD are lacking. However, one nation-wide study conducted in Korea by You et al did 
address AF and OLD treatment in the outpatient setting. Evidence from this study showed that 
patients with OLD and concomitant AF had decreased mortality rates and better symptom 
control on BBs compared to CCBs.10 Additional studies in ED patients with OLD and with 
concomitant rapid AF are necessary to corroborate these findings.  
A few studies examined rate control of AF with RVR in other situations, but their 
outcomes were different from those found in EDs.  Several of these small studies performed in 
outpatient and intensive care unit (ICU) settings revealed that IV metoprolol was the most 
commonly used drug for AF with RVR.  Furthermore, in a study by Moskowitz, et al conducted 
in the ICU setting, IV metoprolol had lower failure rates and required fewer doses to achieve 
rate control compared to either IV diltiazem or IV amiodarone.11 However, the different 
conditions in the ICU in this trial, including aggressive intravenous fluid resuscitation and 
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electrolyte replacement, may have influenced the results. The small sample sizes and disparate 
conditions of these investigations make any comparisons with the ED studies inequitable. 
In summary, these articles point to IV diltiazem, rather than IV metoprolol, as the more 
commonly used agent in the ED setting. While evidence from the Martindale study showed 
that IV diltiazem was superior for rate control of AF with RVR in ED patients, additional 
randomized controlled trials (RCTs) with larger sample sizes and more diverse comorbidities 
among participants are needed to confirm this finding. However, the evidence did confirm that 
both IV diltiazem and IV metoprolol had a similar onset of action and were safe for treatment 
of AF with RVR regardless of a patient’s home medication use and other comorbidities. For 
more conclusive recommendations, future research should include double-blinded RCTs and 
patients with HFrEF and OLD.  
CONCLUSION 
In conclusion, the current evidence suggests that controlling atrial fibrillation with a 
rapid ventricular response in the emergency department setting with a CCB may be superior to 
using a BB because of the CCBs faster onset of action and its ability to control the ventricular 
rate with fewer doses. Furthermore, few statistically significant differences were found for 
adverse reactions due to CCBs compared to those associated with BBs. Calcium channel 
blockers also seemed either equal or superior to BBs for treating AF with RVR in patients with 
HFrEF on chronic BB therapy. One exception to CCBs superiority may be that BBs showed 
better outcomes in OLD patients. However, except for one study conducted by Fromm et al, 
most of these studies had smaller sample sizes or were not double-blinded randomized 
controlled trials.  Therefore, additional research using larger sample sizes and better study 
designs is needed to conclude that CCB’s are superior to BBs for controlling AF with RVR in 
acute settings. What can be derived from the current evidence is that CCBs and BBs are both 
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effective for treatment of AF with RVR; thus, ED medical providers can safely use either class 
of drugs, even in the setting of co-morbidities.  
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